摘要
目的探讨分子靶向药物盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床疗效。方法方便选取该院2014年12月—2016年12月治疗的94例EGFR突变状态明确的晚期非小细胞肺癌患者进行研究,随机分为对照组47例和观察组47例。对照组采用吉非替尼治疗,观察组采用埃克替尼治疗,对比两组的治疗效果、疾病进展与生存时间指标情况。结果在治疗总有效率、疾病进展时间观察组分别为42.5%、(107.39±25.17)d、;对照组分别为34.0%、(105.78±24.56)d、两组差异无统计学意义(P>0.05);在平均生存时间方面,对照组为(159.86±35.69)d,观察组为(240.71±34.23)d,观察组明显更长,差异有统计学意义(P<0.05)。结论分子靶向药物盐酸埃克替尼用于EGFR突变状态明确的晚期非小细胞肺癌的治疗,效果显著,值得临床广泛推广应用。
Objective This paper tries to observe the clinical effect of molecular targeted drugs of icotinib hydrochloride in the treatment of EGFR mutation status of advanced non-small cell lung cancer. Methods 94 cases of advanced non-small cell lung cancer patients with EGFR mutation in this hospital from December 2014 to December 2016 were convenient selected and randomly divided into two groups, 47 cases of the control group and 47 cases of the observation group. The control group was given the treatment of gefitinib, the observation group with icotinib treatment, and then the effect of treatment, disease progression and survival time of two groups were compared. Results The total efficiency of treatment, disease progression time and adverse reactions in the observation group were 42.5%（107.39 ±25.17）d;the control group were 34%,（105.78±24.56）d,with no significant difference（P〉0.05）; in the mean survival time, the control group was（159.86±35.69）d, the observation group was（240.71±34.23）d, the observation group was significantly longer, the difference was statistically significant（P〈0.05）. Conclusion Molecular targeted drugs for the treatment of icotinib, EGFR mutation status clear advanced nonsmall cell lung cancer has significant effect, little side effect, application.
出处
《中外医疗》
2017年第33期148-149,185,共3页
China & Foreign Medical Treatment
